Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.

Context:Genetic polymorphisms in genes of the base excision repair (BER) pathway appear to modulate the therapy response of cancer patients. PARP1 protein recognizes the DNA strand damage and facilitates the subsequent recruitment of BER proteins. Few studies have reported an association betweenPARP1 Val762Alapolymorphism (rs1136410) and cancer therapy response. Objective:The purpose of our study was to determine whetherPARP1 Val762Alapolymorphism have prognostic value in patients with cervical cancer. Materials and methods:Two hundred and sixty adult patients, with histologically confirmed cervical cancer, at FIGO-stages IB2-IVA, primarily treated with concurrent chemotherapy (cisplatin) and radiotherapy. Overall survival (OS) and disease-free survival (DFS) were the primary end points of the analysis. ThePARP1 Val762Alagenetic variants were analyzed by allelic discrimination by real-time PCR. Results:We observed that peri- and postmenopausal women carrying the C-allele present a statistically significant lower OS and DFS (log-rank test,p = 0.008 andp = 0.006, respectively) among those with early stage cervical cancer. Cox regression analysis confirmed these results, after adjustment for other prognostic factors (for OS: HR, 3.70; 95%CI, 1.32–10.38;p = 0.013 and for DFS: HR, 3.97; 95%CI, 1.59–9.93;p = 0.003). Conclusions:This is the first study evaluating the effect of PARP1 Val762Ala polymorphism in treatment response in cervical cancer patients. PARP1 genotypes may contribute as an independent prognostic factor in cervical cancer, being useful in predicting the clinical outcome. [ABSTRACT FROM PUBLISHER]